COVER

2026 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FEATURES

2026 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities

William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.

DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development

Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.

3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine

Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.

ORAL SUSPENSIONS - A New Standard in Oral Suspensions: Leveraging Novel Excipients for FDA Approval

Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).

DRUG DELIVERY - PharmaShell®: Enabling Once-Monthly Therapeutics With Atomic Precision Coatings

Anders Johansson, PhD, Polla Rouf, PhD, and Joel Hellrup, PhD, review an innovative drug delivery system that uses nanometer-thin, inorganic coatings to turn short-acting drugs into long-acting injectables.

PLATFORM TECHNOLOGY - Developing Innovative Solutions to One of the Top Public Health Threats: Antibacterial Resistance

Jennifer Schneider, PhD, believes immunotherapy holds the potential to revolutionize the treatment of “hard to treat,” chronic, and often recalcitrant infections.

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.